medRxiv preprint doi: https://doi.org/10.1101/2020.11.10.20215145; this version posted December 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

The Seroprevalence of SARS-CoV-2 Antibody in the Asymptomatic Population

- 4 Robert L. Stout, PhD and Steven J. Rigatti, MD
- 5 Clinical Reference Laboratory, Inc.
- 6 8433 Quivira Rd Lenexa, KS 66215
- 8 Word count 561
- 9 References 5
- 10 Tables 2

11 Abstract

3

7

12 The seroprevalence of COVID-19 in the self-reported well US population is currently

- unknown. In September we tested a convenience sample of 63,106 life insurance
- 14 applicants for COVID-19 and found a prevalence of 6.6%. This population was
- 15 specifically selected because they were not being evaluated clinically but solely
- being tested for mortality risk. Using 2019 US census estimates this equals more
- than 11.1 million (bootstrap 95% CI: 10.8 11.5 million) asymptomatically infected patients,
- 18 which is double the number of cases reported to CDC as of September 1st.

19 Introduction

- 20 With the imminent introduction of vaccines for COVID-19 it is important to identify
- 21 patients that have previously been asymptomatically infected; they represent two-
- thirds of the infected population. They would be expected to have the least benefit
- from vaccination while also be the group at higher risk of adverse side effects. The
- 24 prevalence of this group in the initial vaccine trials is not adequate to determine the
- residual risk of vaccine induced enhanced respiratory disease¹. FDA has previously
- recognized this risk in their Direction to Vaccine Developers².

27

- In the setting of a pandemic, clinical decisions regarding testing and treatment are
- 29 based on symptoms and the prevalence of the disease in the population. With
- 30 SARS-CoV-2 the spectrum of symptom severity is wide. In the most severe cases

31 testing may not be needed to determine the need for hospitalization, while in less severe illness testing becomes more necessary to determine the proper care setting 32 33 and the need for isolation. A testing strategy is necessarily informed by knowledge of the disease prevalence in the population. In the case of SARS-CoV-2 these 34 estimates have largely been based on the number of laboratory-confirmed cases 35 reported to the CDC as per their mandate³. However, because SARS-CoV-2 is 36 known to produce asymptomatic infection, and not all who are symptomatic obtain 37 38 testing, these reported cases necessarily underestimate the total burden of infection 39 in the population. Since SARS-CoV-2 antibodies persist for weeks or months after 40 infection, the prevalence of these antibodies in a population sample may produce a 41 better estimate of the overall cumulative prevalence of infection. 42 Methods: A national convenience sample of 63,106 life insurance applicants was 43 tested for the presence of antibody to SARS-CoV-2. Blood was obtained as part of the usual underwriting requirements for life insurance. This population was selected 44 45 because they were not being evaluated clinically to diagnosis an illness and were

- 46 individuals that self-reported they were healthy.
- 47

Results: The rate of seroprevalence varied widely by state, was slightly higher for 48 49 females than males, and was strongly negatively associated with age. To estimate 50 the total burden of SARS-CoV-2 infections in the US the total 2019 estimated 51 census population was multiplied by the US population proportion between the ages 52 of 16 and 80 (75.5%). Then, the state-specific proportion of positive tests was 53 applied from our sample. Confidence limits were estimated by generating 5000 54 bootstrap samples (with replacement) of our data and recalculating the total number 55 of US cases. All statistical analyses were performed using R (version 3.6.1) and Rstudio (version1.2.1335)⁴. 56

57

Characteristics of the study population are displayed in Table 1. The distribution by
state is displayed in Table 2. Our seroprevalence-based estimate suggests that
approximately twice the number of SARS-CoV-2 infections have occurred than have
been reported to the CDC. This suggests a much more widespread pandemic, but

62 with lower case rates of hospitalization, complications and deaths. Weaknesses of the study include an imbalanced representation of the US states, as well as the lack 63 64 of samples from those under age 16 or over age 80. Even with these stated limitations the study validates the need for population wide surveillance; for the 65 practicing physician the prevalence data provides a guide to relative risk of infection 66 67 in their minimally or asymptomatic patient population. While the debate continues about the degree and durability of protection afforded by 68 69 prior infection the concern about adverse events may discourage many patients 70 from vaccination. With the limited availability of vaccine it is important to preselect the population at highest risk that is likely to have the greatest benefit. Individuals 71 72 that have had SARS-CoV-2 or that are antibody positive should defer vaccination 73 until the vaccine is more widely available. 74 Additional information: 75 Statement of conflicting interest: 76 Neither Robert Stout, PhD nor Steven Rigatti, MD has any competing interest. Both 77 authors have complete access to all the data in the study and take responsibility for 78 the integrity of the data and analysis. 79 80 Western IRB reviewed the study under the Common Rule and applicable guidance 81 and determined it is exempt under 45 CFR § 46.104(d)(4) using de-identified study 82 samples for epidemiologic investigation. 83 This article has been submitted and approved as a preprint on 84 medRxiv⁵.https://medrxiv.org/cgi/content/short/2020.11.10.20215145v1. 85 86 REFERENCES 87 1.) Tseng C-T, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar 88 89 RL, et al. (2012) Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus. PLoS ONE 90 7(4): e35421. https://doi.org/10.1371/journal.pone.0035421 91 2.) FDA Nonbinding recommendations for "COVID-19-Related Guidance 92

medRxiv preprint doi: https://doi.org/10.1101/2020.11.10.20215145; this version posted December 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

93	Documents for Industry, FDA Staff, and Other Stakeholders," available at
94	https://www.fda.gov/emergency-preparedness-and-response/mcm-
95	issues/covid-19-relatedguidance-documents-industry-fda-staff-and-other-
96	stakeholders
97	3.) Nationally Notifiable Diseases Surveillance System. Coronavirus disease
98	2019 (SARS-COV-2). Accessed July 29, 2020.
99	https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-SARS-
100	<u>CoV-2/</u>
101	4.) Studio Team (2020). RStudio: Integrated Development for R. RStudio, PBC,
102	Boston, MA URL <u>http://www.rstudio.com/.</u>
103	5.) A preprint is posted on medRxiv: The Seroprevalence of SARS-CoV-2
104	Antibody in the Asymptomatic Population
10510	5
106 10710	https://medrxiv.org/cgi/content/short/2020.11.10.20215145v1 7
108	Statement of author contribution:
100	Poport Stout directed the testing of samples combined the demographic data and

109 Robert Stout directed the testing of samples, combined the demographic data and 110 then deleted all identifiable personal information. Reviewed all patient data for

then deleted all identifiable personal information. Reviewed all patien completeness and prepared the initial prevalence estimates.

112 Steve Rigatti Analyzed the prevalence for the data set statistically prepared the

boot-strap adjusted individual state prevalence. He prepared the estimates for

national and state prevalence of asymptomatic COVID-19 infection. Both authors

115 prepared the text

medRxiv preprint doi: https://doi.org/10.1101/2020.11.10.20215145; this version posted December 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Tables 1-2

Table 1: Characteristics of study population by SARS-CoV-2 antibody status. Numeric values shown as median [IQR].

1 p-value by Pearson Chi-square test.

	Negative (58,926) Positive (418)		Total
Sex (% male)	55.3%	53.0%	0.002
Age (yrs)	42 [34-54]	41 [33, 52]	0.000
<30	7746 (90.2%)	837 (9.8%)	8583
30 - 39	17096 (93.3%)	1230 (6.7%)	18326
40 - 49	13537 (93.3%)	976 (6.7%)	14513
50 - 59	10942 (94.1%)	688 (5.9%)	11630
60 - 69	7046 (95.6%)	321 (4.4%)	7367
70+	2559 (95.2%)	128 (4.8%)	2687
Total	58926 (93.4%)	4180 (6.6%)	63106

Table 2: Seroprevalence for September by state.

	%		%		%
NY	15.39	AZ	4.34	CO	2.82
NJ	9.37	SC	4.27	OK	2.83
LA	7.95	MO	4.18	WA	2.53
MS	6.31	MA	4.14	ΚY	2.41
NV	6.18	RI	3.99	NH	2.34
DC	6.07	PR	3.9	UT	2.14
CT	5.99	ΤN	3.87	NC	2.13
FL	5.85	IN	3.69	VT	2.05
DE	5.59	IA	3.35	ND	1.81
GA	5.48	AR	3.29	WV	1.74
MD	5.34	NE	3.24	MT	1.57
MI	5.02	PA	3.23	Ħ	1.33
KS	4.94	ID	3.15	NM	1.33
IL	4.88	MN	3.15	WY	1.33
ΤX	4.85	WI	3.13	OR	1.18
AL	4.83	VA	3.07	ME	0.42
SD	4.44	OH	3.05	AK	0
		CA	3.04		